We are proud to announce our acceptance to the Creative Destruction Lab (CDL) Cancer program. Partnered with the Canadian Cancer Society, this unique non-profit program brings together global leaders and experts across the cancer care continuum to support technology innovations that improve the cancer experience, from prevention to diagnosis, treatment, and survivorship. The program includes sessions to sharpen objectives, prioritize time and resources, raise capital, and engage with experts working on the frontiers of research. The mission of the CDL Cancer program is to confront the escalating global incidence of cancer by championing the commercialization of technologies that will enable the future of personalized cancer care at scale, while enhancing access and reducing healthcare costs worldwide.
INNOVOTEX Canadian Strategy:
We recently completed our preclinical proof-of-concept data set and developed strategies with industry partners towards the completion of our pre-clinical development within the Canadian life science ecosystem. The Canadian market provides multiple opportunities to engage with experienced mentors who built and exited therapeutic companies and provides a wealth of resources to support our capital needs towards a clinical trial.